News

A-CUBE is a venture capital-backed company funded by JAIC and yet2.com, which uses proprietary in silico algorithms to predict and monetize novel drug targets related to blockbuster drugs.

Through the partnership, the NextGen integrated technology platform will connect the Wills Eye community, giving care providers access to electronic health records and enabling exchange of patient data

In Australia, Aspen and Sigma‘s Pharmaceutical Division compete in a number of pharmaceutical markets, including in the supply of various prescription generic medicines and over-the-counter pharmaceutical products. In

Generex claims that the new Canadian Patent no. 2,354,148 titled Aerosol Formulations for Buccal and Pulmonary Application increases the number of issued patents related to the its buccal

Repligen claims that RG3039 is an inhibitor of an RNA processing enzyme which targets increased production of SMN, a protein of deficient levels in patients with SMA. The

Achievement of the milestone has entitled Envoy to receive a cash payment from Merck. The milestone was linked to Envoy successfully applying its bacTRAP technology in certain tissues

E7040 is a hydrophilic microspherical particle produced from a polyvinyl alcohol polymer. Eisai said that E7040 is an embolic bead that is injected through a catheter to physically

A-623 will be manufactured in the Billingham, UK facility of the network. Anthera Pharma has previously begun enrollment in Pearl-SC, a Phase 2b clinical study in Lupus patients,

Tessalon, an FDA approved drug to treat symptomatic relief of cough in patients older than 10, may attract younger children as the drug has a candy-like appearance –